Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation

• Published in: The Journal of clinical investigation Vol. 132; no. 23; pp. 1 - 15
• Main Authors: Ebert, Maximilian, Jerke, Uwe, Eulenberg-Gustavus, Claudia, Kling, Lovis, Jenne, Dieter, Kirchner, Marieluise, Mertins, Philipp, Bieringer, Markus, Elitok, Saban, Eckardt, Kai-Uwe, Schreiber, Adrian, Salama, Alan D, Kettritz, Ralph
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.12.2022
• Subjects: a1-antitrypsin; alpha 1-Antitrypsin - metabolism; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; Antigens; Antineutrophil cytoplasmic antibodies; Autoantibodies; Autoimmunity; Biomedical research; Cell activation; Cell surface; Clinical Medicine; Disease; Flow cytometry; Fluorescence resonance energy transfer; Giant Cell Arteritis; Humans; Immunoblotting; Inflammation; Leukocytes (neutrophilic); Methionine; Methionine - metabolism; Mucocutaneous Lymph Node Syndrome; Myeloblastin - genetics; Neutrophil Activation; Neutrophils; Oxidation; Patients; Peroxidase; Peroxidase - genetics; Peroxidase - metabolism; Plasma; Proteinase 3; Proteins; Remission (Medicine); Surface plasmon resonance; Valine; Vasculitis; Autoimmunity; Innate immunity; Inflammation; Vasculitis
• ISSN: 1558-8238; 0021-9738; 1558-8238
• DOI: 10.1172/jci160089

BackgroundAntineutrophil cytoplasmic autoantibody-associated (ANCA-associated) vasculitidies (AAV) are life-threatening systemic autoimmune conditions. ANCAs directed against proteinase 3 (PR3) or myeloperoxidase (MPO) bind their cell surface-presented antigen, activate neutrophils, and cause vasculitis. An imbalance between PR3 and its major inhibitor α1-antitrypsin (AAT) was proposed to underlie PR3- but not MPO-AAV. We measured AAT and PR3 in healthy individuals and patients with AAV and studied protective AAT effects pertaining to PR3- and MPO-ANCA.MethodsPlasma and blood neutrophils were assessed for PR3 and AAT. WT, mutant, and oxidation-resistant AAT species were produced to characterize AAT-PR3 interactions by flow cytometry, immunoblotting, fluorescence resonance energy transfer assays, and surface plasmon resonance measurements. Neutrophil activation was measured using the ferricytochrome C assay and AAT methionine-oxidation by Parallel Reaction Monitoring.ResultsWe found significantly increased PR3 and AAT pools in patients with both PR3- and MPO-AAV; however, only in PR3-AAV did the PR3 pool correlate with the ANCA titer, inflammatory response, and disease severity. Mechanistically, AAT prevented PR3 from binding to CD177, thereby reducing neutrophil surface antigen for ligation by PR3-ANCA. Active patients with PR3-AAV showed critical methionine-oxidation in plasma AAT that was recapitulated by ANCA-activated neutrophils. The protective PR3-related AAT effects were compromised by methionine-oxidation in the AAT reactive center loop but preserved when 2 critical methionines were substituted with valine and leucine.ConclusionPathogenic differences between PR3- and MPO-AAV are related to AAT regulation of membrane-PR3, attenuating neutrophil activation by PR3-ANCA rather than MPO-ANCA. Oxidation-resistant AAT could serve as adjunctive therapy in PR3-AAV.FUNDINGThis work was supported by KE 576/10-1 from the Deutsche Forschungsgemeinschaft, SCHR 771/8-1 from the Deutsche Forschungsgemeinschaft, grant 394046635 - SFB 1365 from the Deutsche Forschungsgemeinschaft, and ECRC grants.